Tag archive for ‘Dendreon Corporation’
2011 Is The Crucial Year for Provenge and Dendreon (DNDN, $34.59)
Summary and Overview Dendreon began the marketing of Provenge, its cancer vaccine for prostate cancer in May of 2010. Enthusiasm following approval drove the price of Dendreon to $56 on May 3, 2010. Subsequently, concerns arose that caused the stock to settle back into the mid to high $30s. In this note we go through […]